PhaseBio Diabetes Program Reaches Inflection Point With Series B Add-On
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held biotech announces an additional $23 million raise from existing investors to finance a head-to-head Phase IIb trial for its GLP-1 analogue against Victoza.
You may also be interested in...
With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
Twice delayed by “complete response” letters, the drug’s approval gives Amylin a once-weekly GLP-1 analog, the longest-acting drug in its class.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.